Search
ProQR Therapeutics NV
PRQRAdd to Watchlist
1.880USD
+0.210+12.57%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
202.50MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-17The current earnings forecast score of ProQR Therapeutics NV is 8.67, ranking 71 out of 388 in the Biotechnology & Medical Research industry. The average price target is 9.50, with a high of 14.00 and a low of 5.00.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
9.000
Target Price
+476.92%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
ProQR Therapeutics NV
PRQR
9
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
25
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is ProQR Therapeutics NV's expected revenue for the next quarter?
ProQR Therapeutics NV's expected revenue is 5.31M.
What is ProQR Therapeutics NV's price target?
Analysts forecast that ProQR Therapeutics NV's price target is USD 9.50, with the highest forecast at USD 14.00 and the lowest forecast at USD 5.00.
How have ProQR Therapeutics NVPRQR's recent earnings per share performed?
The market expectation was USD -0.15, while ProQR Therapeutics NVPRQR's earnings per share (EPS) for the previous quarter was USD -0.10. EPS for the next quarter is expected at USD -0.14.
What is the analyst rating for ProQR Therapeutics NV?
Based on the ratings of ProQR Therapeutics NV's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
